Avirax Pharmaceuticals PLC offers a comprehensive range of WHO prequalified ARV medicines, with a core objective of improving access and affordability for patients globally. We are proud to support National AIDS treatment programs in Africa and other regions, contributing to the global fight against HIV/AIDS.

In 2004, we partnered with the Clinton Health Access Initiative (CHAI) to help reduce the cost of the triple drug cocktail for consortium partners in Africa and other countries, furthering our commitment to improving the lives of those affected by HIV.

Our portfolio includes bio-equivalent ARV medicines and Active Pharmaceutical Ingredients (APIs), all produced at our state-of-the-art WHO prequalified manufacturing facilities in India, a PIC/S approved manufacturing facility in South Africa, and a manufacturing facility in Russia.

With a range of first-line and second-line Highly Active Antiretroviral Therapy (HAART) regimens, Avirax Pharmaceuticals PLC aims to play a significant role in the ongoing fight against HIV/AIDS, improving the health and well-being of patients worldwide.